Healthcare Experience Foundation (HXF) Special Report: New Data Reveals First Look at Emerging Patient Experience Trends for Healthcare Delivery Following Mandated Updates to National Consumer Survey
"With recent updates to the HCAHPS survey we're able to see for the first time in nearly 20 years, nationally, empirical data confirming just how critical collaboration among healthcare teams is to shaping the patient experience."
Share
The report reveals an industry first-look at initial findings of data collected and analyzed from over 18,000 patient discharge surveys administered and collected in Q1 2025 from healthcare systems across the United States. The findings represent a first-of-its-kind glimpse into patients' perceptions of quality care following a comprehensive nation-wide update earlier this year to the annual Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey—the largest update to the survey since its inception in 2006.
'For years, we've recognized—anecdotally and through experience—that strong team dynamics are essential to delivering exceptional patient care. With recent updates to the HCAHPS survey we're able to see for the first time in nearly 20 years, nationally, empirical data confirming just how critical collaboration among healthcare teams is to shaping the patient experience,' says Katie Owens, President of Healthcare Experience Foundation. 'The data was not previously available because care coordination items did not exist in past HCAHPS iterations,' she adds, 'and reveals that collaboration across teams is a more important predictor of patient experience than other factors previously measured.'
As a national, standardized, publicly reported data collection instrument developed by the Centers for Medicare & Medicaid Services (CMS), the HCAHPS survey measures patients' perspectives of their hospital experiences, including hospital quality and overall patient care.
Other key findings from the Special Report include:
Physicians and staff continue to drive overall patient experiences, but data reveals that nurses especially, who often have the most consistent and direct interactions with patients, are key influencers of overall care experience.
Data reveals how quickly care teams respond to patient needs ranks third highest predictor of overall hospital rating, higher than other measures including restfulness and cleanliness of the hospital environment, physician communications, discharge information, and information about symptoms.
Nearly 2 out of 3 patients (65.7%) report that their hospital stay was unplanned, underscoring the importance of care coordination across emergency and inpatient settings—further validating patients desires or seamless teamwork.
'The survey is evolving to increase value for both patients and healthcare teams,' said Steve Meth, Vice President and Chief Experience Officer at Johns Hopkins Medicine. 'This wet read not only helps amplify healthcare consumers priorities about what matters most in their care, but also reveals actionable insights for healthcare leaders to respond nimbly to patient feedback.'
About Healthcare Experience Foundation:
Healthcare Experience Foundation (HXF) is a national leader in healthcare coaching and consulting, serving more than 7,500 healthcare leaders and staff across 600+ organizations. With an average improvement of 24 national percentile points in HCAHPS performance, HXF empowers teams to lead with empathy, purpose, and excellence. Learn more at healthcareexperience.org. Healthcare Experience Foundation proudly powers PRC's Advisory, Coaching and Improvement Division. For more information, visit www.healthcareexperience.org.
About PRC:
Professional Research Consultants (PRC) is a leading experience management company dedicated to helping healthcare organizations create world-class experiences for patients, employees, physicians, and communities. Since 1980, PRC has partnered with over 2,800 healthcare organizations nationwide, delivering actionable insights through its proprietary healthcare discovery platform. PRC's solutions empower organizations to listen, understand, and act—driving measurable improvements in patient loyalty, employee engagement, physician alignment, and community health. Learn more at
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
13 minutes ago
- Business Wire
Elation Survey Finds Nearly 40% of Primary Care Physicians Use AI-powered Tools for Daily Clinical Documentation
SAN FRANCISCO--(BUSINESS WIRE)-- Elation Health, the clinical-first technology company powering innovation in primary care, today announced the results of its latest AI in Primary Care survey of 291 primary care physicians, focused on the current sentiments, adoption patterns, critical concerns (defects), key behavioral insights (learnings), and explicit user desires (requests) regarding the integration of Artificial Intelligence (AI) in primary care workflows. The analysis reveals 39.3% use AI-powered tools daily, specifically for clinical documentation. The survey also revealed that clinicians have a clear hierarchy of needs when it comes to AI, with fundamental performance factors at the top of that hierarchy. With 59% of respondents in agreement, accuracy and reliability ranked as the most important factor when evaluating AI tools. Seamless workflow integration and ease of use followed at 22%, while efficiency and time savings (ROI) came in at 13%, and cost affordability at 6% (see Table 1). Table 1: Most Important Factors in Choosing an AI Tool 'Our survey confirms what we already suspected: clinicians are cautiously optimistic about AI's potential, but they're looking for thoughtful, trustworthy, affordable solutions that truly fit the realities of primary care,' said Sara Pastoor, MD, MHA, FAAFP, and director of primary care advancement for Elation Health. 'At Elation, we're applying AI in ways that are context-aware, and fit naturally into clinical and operational workflows to enable high-quality care hand in hand with long-term financial success.' While the survey also affirmed the general attitude towards AI in clinical settings is predominantly positive, a notable segment remains neutral or skeptical. Although a combined 59% of respondents rate their sentiment as "Positive" or "Very Positive," 24% of respondents were 'Neutral' in their sentiments about AI. This sizable group appears to be open to AI advancements but may be likely waiting for clear evidence of its value, reliability, and ease of use before fully embracing it. These findings reinforce how Elation approaches research and development with Elation's Innovation Labs that leverage a dynamic, interactive product development and testing framework to allow it to work shoulder-to-shoulder with clinicians and staff through design cycles, usability testing, and continuous in-product feedback. This ensures Elation is developing AI in ways that clinicians trust and find valuable. Elation Health's clinical-first approach to AI is distinguished by continuous, hands-on collaboration with primary care clinicians throughout the Elation Labs development process. Every new AI capability is shaped directly by clinician feedback, gathered through design cycles, usability testing, and ongoing in-product input. Elation's iterative, transparent partnership with customers ensures that its AI features are clinically relevant, trustworthy, and seamlessly integrated into daily workflows, empowering clinicians while keeping the focus firmly on patient care. The survey was conducted with 291 independent primary care clinicians who are current Elation Health customers. For more on the results from Elation's State of AI in Primary Care Clinical Practice survey, visit here. To join Elation's product developers for a live, interactive webinar to explore how ethical, clinician-designed AI embedded within the EHR is transforming primary care by reducing burnout, improving care quality, and empowering both clinicians and patients: register here. About Elation Elation Health is the clinical-first AI platform for primary care success. Trusted by over 36,000 clinicians and 20 million patients, Elation's EHR and billing solutions combine proven clinical workflows with responsible, predictive AI - purpose built for primary care. The company's clinical-first approach puts physicians at the center, delivering trusted, transparent innovation that saves time and sustains meaningful patient relationships. Elation Health is recognized as Best in KLAS for its commitment to excellence in primary care technology. Learn more at and on LinkedIn.
Business Wire
13 minutes ago
- Business Wire
FineHeart Named Leader of the IPCEI Health Tech4Cure to Spearhead the Structuring of the European Implantable Medical Device Sector
BORDEAUX, France--(BUSINESS WIRE)--FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, has been designated as the lead partner of the IPCEI Tech4Cure (Important Project of Common European Interest), dedicated to the implantable medical device (IMD) sector. This project is jointly notified by six EU Member States – France, Hungary, Italy, Latvia, Slovakia, and Slovenia FineHeart will carry out its SmartDMIA program to structure the innovative active implantable medical device (AIMD) sector, which is essential for public health and Europe's industrial autonomy, in synergy with other European laureates of the Tech4Cure program. Arnaud Mascarell, CEO and co-founder of FineHeart, said: " Being named leader of the IPCEI Tech4Cure with our SmartDMIA project is a source of immense pride. It is the recognition of our innovation ability and our technological and industrial leadership. This project will strengthen our sustainable growth and increase our international visibility. Together with our academic and industrial partners, we will build a sovereign, competitive and sustainable AIMD industry serving the health of European citizens." The Smart DMIA project will cover the entire value chain—from design to industrialization—of next-generation active implantable medical devices (AIMDs), for which energy supply is a major technological and medical challenge. The main development areas are: Extending the lifespan of encapsulated electronic components, enabling the integration of miniaturized transcutaneous energy and data transfer systems Developing universal interoperability between devices, regardless of their power (from a few milliwatts to 30 W), to optimize energy management and diagnostics and promote personalized medicine (5P medicine) Harmonization of standards for communication, cybersecurity, and interconnection with hospital systems and digital platforms. FineHeart will leverage its R&D know-how perfected during the development of FlowMaker®, the world's first and only miniaturized, fully implantable, wireless cardiac flow accelerator with no external battery for the treatment of advanced heart failure. This breakthrough device, currently in European clinical trials, adapts to the progression of the disease and provides physiological support synchronized with the heart's natural contractions. Through this pioneering role, FineHeart has become a strategic player in the transformation of the European AIMD sector, contributing its expertise and supporting European industrial competitiveness. About the PIIEC Launched by France in 2022, the PIIEC Santé aims to create a "Europe of Health" by promoting the emergence of European champions in disruptive technologies in the sector. This initiative aims to strengthen European production capacities in the health field, while stimulating the formation of ambitious European partnerships around innovative projects, thus ensuring European sovereignty. Coordinated by the Directorate-General for Enterprise (DGE), this project is being rolled out in two complementary waves: the first, authorized on May 28, 2024, targets essential medicines and critical molecules (Med4Cure); the second, entitled Tech4Cure, is dedicated to innovative MedTech medical devices (Tech4Cure). Tech4Cure aims to establish projects at European level focusing on: The lifespan of active implantable medical devices, in particular the lifespan of batteries and any components, materials, and technologies designed to extend the lifespan of active implantable medical devices, thereby promoting the digital and ecological transition. Connected and portable medical imaging solutions to promote more compact imaging devices, harnessing the potential of AI and IoT to facilitate remote examinations and increase the pool of available equipment. Sustainable design of medical devices, by strengthening the ecological transition in the design of medical devices, in particular through the use of biomaterials and eco-design to stimulate innovation in raw material supply and sustainability. About FineHeart - FineHeart
Business Wire
2 hours ago
- Business Wire
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENSai™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials. The platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. Share 'ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars,' said Dr. Jennifer Bath, President & CEO, IPA. 'With LENSai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules.' Late‑stage ADA failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. Yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑MHC II binding across a few dozen HLA alleles—leaving large swaths of immune diversity untested and immunogenic 'self/non‑self' checks largely unaddressed. LENSai's HYFT‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. It evaluates nearly 900 HLA variants and performs a whole‑proteome 'humanness' scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. By revealing design‑level fixes before expensive animal studies or repeat GMP production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. Study Highlights 217 marketed and clinical-stage antibodies analyzed – the largest public ADA dataset to predict immunogenicity risk – the largest public ADA dataset to predict immunogenicity risk Single composite score tracks clinical reality – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92. – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92. Alignment-free, HYFT-powered engine – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. Detailed amino acid and epitope-level immunogenicity 'self' scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays. Read the full case study: [link] About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Forward-Looking Statements This press release contains forward looking statements within the meaning of applicable United States and Canadian securities laws. Forward looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' 'potential,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. Examples include statements regarding the projected performance, scalability, and market adoption of the Company's LENSai™ Immunogenicity Screening; the ability of its HYFT® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ADA prediction on biopharma R&D efficiency; and the Company's broader scientific, commercial, and capital markets objectives. Forward looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results could differ materially from those expressed or implied because of factors beyond the Company's control, including the pace of scientific and technological innovation in AI driven drug discovery, the accuracy and regulatory acceptance of in-silico ADA risk screening, competitive shifts as the industry transitions away from MS dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. Additional information about these and other risks and uncertainties is set out in the Company's Annual Report on Form 20F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at If any of these risks materialize, the Company's actual results, performance, or achievements could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on forward looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.
